Pfizer Korea Upjohn, last year's sales were ￦385.8 billion

Difference from global sales proportion

Pfizer + Upzone sales performance grew 6.4% compared to 2018

It was confirmed that the annual sales of Pfizer Korea Upjohn, which was split from Korea Pfizer Pharmaceuticals last year, amounted to ￦385.8 billion.

 

Korea Pfizer Pharmaceuticals(￦395.7 billion) is not much different.

 

Considering that Pfizer and the Pfizer Upjohn have a global sales ratio of 8 to 2, the sales share of Pfizer Upjohn in Korea is high.

 

According to the audit report of Pfizer Korea Pharmaceuticals and Pfizer Korea Upjohn submitted to the Financial Supervisory Service on the 9th, the sales of the two companies over the past year (December 2018 to November 2019) totaled a total of ￦745.5 billion.

 

The fiscal year of Pfizer Korea Pharmaceuticals and Pfizer Korea Upjohn is November, and the results are calculated from December of the previous year to November of this year.

 

Of these, Pfizer Pharmaceuticals' sales were ￦395.7 billion.

 

This is a 7.2% increase from 2018's ￦369.1 billion.

 

It recorded an operating loss of ￦1.1 billion.

 

However, in 2018, the operating loss decreased from ￦2.3 billion.

 

The sales of Pfizer Korea Upjohn were ￦385.8 billion.

 

This sales amount is calculated by adding the sales of the patent expiration business departement to ￦205.8 billion and the sales from May 27, 2019 to November 30, 2019, to be ￦ 179.9 billion.

 

This is an increase of 5.6% compared to ￦365.3 billion in 2018.

 

Operating profit was ￦15.8 billion before division and ￦5.4 billion after the division, operating profit fell to a third.

 

Sales of Pfizer Korea in the past 5 years (Unit: ￦100 million, The FSS)

The size of Pfizer Korea Upjohn with annual sales of ￦385.8 billion is comparable to that of domestic mid-sized pharmaceutical companies.

 

The share of sales between Pfizer Korea and Pfizer Korea Upjohn is equal to 50.6% versus 49.4%.

 

Considering that Pfizer Korea Upjohn deals only with patent-expired drugs, industry officials say that sales proportion is unusually high.

 

This is analyzed because of the characteristics of the Korean market with high original loyalty.

 

The representative example of Pfizer Korea Upjohn is Lipitor.

 

Since its launch in 1999, Lipitor has been ranked first and second in outpatient prescriptions.

 

Lipitor's 10mg insurance price was cut from ￦1241 to ￦644 in 2007, and as the patent expired in 2009, more than 130 generic products were released, but Lipitor’s prescription amount increased.

 

Last year, Lipitor had the most outpatient prescriptions.

 

It was prescribed ￦176.2 billion, an increase of 8.4% from ￦162.6 billion in 2018.

 

The share of sales in Pfizer Korea Upjohn, which is the highest in Korea, is also confirmed by comparison with global.

 

According to a 2019 report released by Pfizer earlier this year, Pfizer's global sales last year were $51.7 billion (about ￦63 trillion).

 

Of these, Pfizer Korea Upjohn's sales are $10.2 billion (about ￦12 trillion).

 

The proportion is only 19.8%.

 

Global and Pfizer Korea vs.

 

Pfizer Korea Upjohn sales share.

 

Pfizer Korea Upjohn

Previously, Pfizer divided Pfizer Korea Upjohn on May 27 last year.

 

The key is to manage patent expiration drugs by Pfizer Korea Upjohn.

 

Representative items such as Lipitor, Novasc (Amlodipine), and Celebrex (Celecoxib) have been moved to the Pfizer Korea Upjohn.

 

The newly established division, Pfizer Korea Upjohn, plans to merge with Mylan and change its name to Viatris and start again by September.